#GLP-1 class
Coverage of the GLP-1 receptor agonist family and its successors.
GLP-1 Drugs and Kidney Outcomes in CKD
Thirteen GLP-1 receptor agonist trials pooled in chronic kidney disease show fewer heart and kidney events, with semaglutide topping an exploratory ranking.
Tirzepatide May Ease Beta-Cell Hypoxia
A mouse and cell study finds tirzepatide, GLP-1, and GIP suppress high-glucose-induced beta-cell hypoxia through a cAMP/PKA pathway.
Missed Doses of Oral vs Weekly Semaglutide
A Novo Nordisk research letter models what missing doses does to drug levels for oral semaglutide versus once-weekly GLP-1 injections.
An RNA Therapy for Muscle Loss on GLP-1s
In mice, a new RNA-based therapy paired with semaglutide preserved more lean mass than semaglutide alone, though it remains far from human use.
Semaglutide in Children: England's Data
A corrected conference abstract from 35 English specialist clinics reports how 406 children and young people fared on semaglutide.
Semaglutide vs retatrutide: one vs three
Semaglutide hits one receptor and has cardiovascular outcome data. Retatrutide hits three and is still investigational.
BMJ writers win MJA journalism awards
BMJ journalists won four 2026 MJA Awards for reporting on Mounjaro access, medical misogyny, and Trump-era health policy.
GLP-1 drugs and hidradenitis suppurativa
A new review asks whether semaglutide and other GLP-1 drugs could help hidradenitis suppurativa. The evidence is early, and this is not an approved use.
Oral semaglutide 25 mg vs the injection
A Novo Nordisk funded indirect comparison put oral semaglutide 25 mg against the 2.4 mg injection. The weight-loss gap was about one percentage point.
Orforglipron liver safety: pooled data
A pooled analysis of 11,220 people across seven orforglipron phase 3 trials found no confirmed drug-induced liver injury. Here is what it checked, and did not.
PT-141 vs semaglutide: two brain targets
Both peptides act on brain receptors, and that is where the similarity stops. One is licensed for low sexual desire, the other for weight and heart risk.
What the EVOKE Alzheimer's trials found
In the EVOKE and EVOKE+ trials, oral semaglutide reduced Alzheimer's-linked biomarkers but did not slow cognitive or functional decline.